Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) S...
Aquestive Therapeutics, Inc. (AQST)
Last aquestive therapeutics, inc. earnings: 3/11 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.aquestive.com/investor-relations
Company Research
Source: Yahoo! Finance
Announces immediate availability of Libervant 5mg, 7.5mg, 10mg, 12.5mg, and 15mg for patients between 2 to 5 years of age Company track record now includes 4 FDA approvals since 2018 Anaphylm program on track; NDA submission expected by the end of 2024 Hosts conference call for investors on April 29 at 8:00 a.m. ET WARREN, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the U.S. Food and Drug Administration (FDA) has approved Libervant™ (diazepam) Buccal Film for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e ., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy between 2 to 5 years of age. “We are thrilled to have received
Show less
Read more
Impact Snapshot
Event Time:
AQST
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AQST alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AQST alerts
High impacting Aquestive Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AQST
News
- Global Oral Transmucosal Drugs Market Size To Exceed USD 62.3 Billion By 2033 | CAGR Of 6.5% [Yahoo! Finance]Yahoo! Finance
- Aquestive Therapeutics, Inc. (NASDAQ: AQST) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.MarketBeat
- Aquestive Therapeutics, Inc. (NASDAQ: AQST) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $8.00 price target on the stock.MarketBeat
- Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Aquestive Therapeutics, Inc. (NASDAQ:AQST) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year [Yahoo! Finance]Yahoo! Finance
AQST
Earnings
- 5/7/24 - Miss
AQST
Sec Filings
- 5/13/24 - Form 4
- 5/13/24 - Form 4
- 5/8/24 - Form 8-K
- AQST's page on the SEC website